- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03576599
Intravenous Bisphosphonate in Stress Fracture Treatment -A Randomised Controlled Double Blinded Multicenter Trial
Intravenous Bisphosphonate in Stress Fracture Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomised controlled multicenter trial. Prospective study. The trial will be performed in accordance with the CONSORT-statement. The inclusion period will be two years. The patients will be randomised to standard treatment (casting, partial weight-bearing, orthotic insoles) in addition to either zoledronic acid or placebo (saline) infusions. The randomization process will be carried out through a web based randomization service (Norwegian University of Science and Technology, Unit for applied clinical research). Patient data will be kept and organized by a study coordinator (nurse) and will not be revealed for the clincal investigators, except in medical emergency situations. In such cases, the patient will be excluded from the study. A number of bottles containing zoledronic acid or placebo will be available in each of the participating hospitals. The bottles containing zoledronic acid and placebo are visually identical, numbered from 1 through 80 (two bottles with similar number, the second bottle will be kept for the second infusion). The patients will be randomised in blocks, creating evenly sized groups given zoledronic acid or placebo. When a patient is included and thereafter randomised, the study coordinator decides which bottle number to be given and provides this information to the physician. The study coordinator is the only person in the study group which is not blinded.
On the first visit, the included patients will undergo clinical examination and baseline parameters will be registered. If MRI is not previously obtained, this will be performed as quickly as possible. The clinical controls will be scheduled 4 and 12 and 26 weeks thereafter, the latter including MRI. If healing has still not occured, the patients will be given the second infusion and meet for clinical examination every 4 weeks until healing. Clinical healing is defined as painless or near painless (VAS pain 0-2) weight bearing. If healing has not occured 12 months after inclusion, surgery will be considered.
MRI will be obtained at (or before) baseline, 6 months and one year. MRIs will be examined by a blinded radiologist. Bone marrow lesions (BMLs) will be measured (area and volume) and fracture lines registered.
All patients (both groups) will be prescribed calcium and vitamin D (Calcigran Forte 500mg/400IE) taken orally once daily in the whole study period. This is recommended as an adjunct to bisphosphonate treatment on a general basis/standard treatment and is not to be investigated separately.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0450
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-70 years
- Stress fractures in the foot. A stress fracture is defined as a fracture occured after repetitive trauma, with characteristic MRI findings (ref) and distinctive pain over the fracture site at weight bearing.
- at least 6 months of pain history
- compliant patient
- non-aided ambulatory patient prior to the injury
Exclusion Criteria:
- Ongoing use of bisphosphonates, PTH/PTH-analogues or use within 12 months prior to the injury
- Use of bisphophonates for more than 6 months within the last 5 years
- Intolerance to zoledronic acid
- Renal failure (GFR<30)
- S-25(OH)vitD > 25
- pregnancy
- breast feeding
- hypocalcemia
- MRI contraindications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Zoledronic Acid Injectable Product
Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
|
One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
Other Names:
|
Placebo Comparator: Placebo
Patients randomized to Placebo infusion (saline), repeated after 3 months
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The American Orthopedic Foot and Ankle Score (AOFAS) mid foot scale
Time Frame: 1 year
|
a scale evaluating pain, function and alignment of the foot.
0-100, With 100 as maximum score
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual analoge scale (VAS) for pain
Time Frame: 3, 6, 8, 10 and 12 months
|
Patient Reported Outcome Measure (PROM) for evaluating local pain
|
3, 6, 8, 10 and 12 months
|
Change in bone marrow lesions evaluated by magnetic resonance imaging (MRI)
Time Frame: 1 year
|
the intensity and the amount of bone marrow oedema is evaluated
|
1 year
|
The American Orthopedic Foot and Ankle Score (AOFAS) mid foot scale
Time Frame: 3, 6, 8, 10, 12 months
|
a scale evaluating pain, function and alignment of the foot
|
3, 6, 8, 10, 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Elisabeth E Husebye, PhD, Oslo University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REK 2014/1986
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Fracture Foot
-
Balgrist University HospitalRecruitingStress Fracture Metatarsal | Lower Limb Fracture | Stress Fracture Foot | Stress Fracture Ankle | Stress Fracture of TibiaSwitzerland
-
Zimmer BiometCompletedStress Fracture | Insufficiency Fractures | Stress Fracture, Ankle, Foot and ToesUnited States, Canada
-
Inion OyRecruitingFractures, Bone | Foot Deformities | Ankle Fractures | Hallux Valgus | Hallux Rigidus | Fracture of Foot | Lisfranc Fracture | Metatarsalgia | Lisfranc Injury | Deformity, Foot | Calcaneus Fracture | Talus Fracture | Medial Malleolus Fracture | Navicular Fracture | Foot Fracture | Foot Injury | Feet Deformity Tarsus | Deformity... and other conditionsFinland
-
Brooke Army Medical CenterUniformed Services University of the Health Sciences; The Geneva FoundationRecruitingMetatarsal Stress Fracture | Stress Fracture of TibiaUnited States
-
Fundación Garcia CugatCompletedEffectiveness of Shockwave Treatment for Proximal Fifth Metatarsal Stress Fracture in Soccer PlayersStress Fracture MetatarsalSpain
-
University of Central LancashireCompletedTibial Stress Fracture
-
University of South CarolinaUnited States Department of Defense; Eisenhower Army Medical Center; Moncrief...Enrolling by invitationStress Fracture of Tibia or FibulaUnited States
-
University of South CarolinaWashington University School of MedicineNot yet recruitingStress Fracture | Fracture Healing | Military TrainingUnited States
-
Creighton UniversityGlaxoSmithKline; United States Department of DefenseCompletedStress FractureUnited States
-
Hospital do CoracaoEnrolling by invitationAnkle Injuries | Ankle Fractures | Foot Injuries and Disorders | Foot FractureBrazil
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States